| __timestamp | Protagonist Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 1499100000 |
| Thursday, January 1, 2015 | 2963000 | 1923500000 |
| Friday, January 1, 2016 | 6961000 | 2351400000 |
| Sunday, January 1, 2017 | 11779000 | 2564000000 |
| Monday, January 1, 2018 | 13697000 | 2397300000 |
| Tuesday, January 1, 2019 | 15749000 | 2503400000 |
| Wednesday, January 1, 2020 | 18638000 | 3344600000 |
| Friday, January 1, 2021 | 27196000 | 4529200000 |
| Saturday, January 1, 2022 | 31739000 | 4179100000 |
| Sunday, January 1, 2023 | 33491000 | 4650100000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Protagonist Therapeutics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outspent Protagonist Therapeutics, with SG&A expenses peaking at approximately $4.65 billion in 2023, a staggering 13% increase from 2020. In contrast, Protagonist Therapeutics saw a more modest rise, with expenses growing from $1.86 million in 2014 to $33.49 million in 2023, marking an impressive 1,700% increase. This disparity highlights the differing scales and strategies of these companies, with Viatris focusing on expansive operations and Protagonist on targeted growth. As the industry continues to shift, these spending patterns offer a glimpse into the strategic priorities shaping the future of pharmaceuticals.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Protagonist Therapeutics, Inc.
Amgen Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Summit Therapeutics Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and Insmed Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or Madrigal Pharmaceuticals, Inc.
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viatris Inc. and Evotec SE
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends